The strategy to achieve SysProts objective is an innovative, explorative systems biology approach, both on the molecular and physiological level with a strong focus on protein function and modification. The project is producing high quality proteomics data indispensable for the identification of novel circulating protein factors and posttranslational protein modifications that are important for the onset, dynamics and progression of adipositas and type II diabetes. Data generation is complemented by the development of computational analysis methods for these novel data types and creation of an adequate modelling technology. Recently the pharmaceutical company Pfizer has launched a comparable US$14-million systems-biology consortium to improve the understanding of diabetes and obesity (Nature, Vol. 453, 8 May 2008).
SysProt started January 2007 with the support of the EU (FP6-2005-LIFESCIHEALTH-7). Additional information is provided on the project website: www.sysprot.eu